Changes this week
Changes detected in the 7 days to Nov 21, 2026
- Minor: EP-104GI · Eosinophilic Esophagitis (EoE) Trial sites expanded: 23 → 33 locations
- Minor: Afimkibart · Rheumatoid Arthritis Trial sites expanded: 10 → 17 locations
- Minor: LX2006 Gene Therapy in Friedreich Ataxia Cardiomyopathy Trial sites expanded: 1 → 22 locations
- Minor: EPI-326 in EGFR-mutant NSCLC and HNSCC Trial sites expanded: 6 → 12 locations
- Minor: Methylene Blue Photodynamic Therapy · Deep Tissue Abscesses Enrollment increased: 120 → 150 participants
- Minor: S241656 in Selected RAS/MAPK Mutation- Positive Malignancies Enrollment increased: 554 → 623 participants
- Minor: VIR-5500 (AMX-500) in Prostate Cancer Trial sites expanded: 26 → 30 locations
- Minor: CD388/MK1406 on the Immunogenicity of Fluzone® HD Vaccine (CD388.SQ.1.08/MK-1406-007) Trial sites expanded: 4 → 15 locations
- Minor: Carnosine · Peripheral Arterial Disease Patients Enrollment reduced: 144 → 120 participants
- Minor: TOS-358 · HR+ HER2- Breast Cancer Trial sites expanded: 18 → 25 locations
- Minor: Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry Trial sites expanded: 318 → 324 locations
- Minor: Antitumor Activity of Ivonescimab Plus Pemetrexed and Platinum-Based Chemotherapy in Advanced Malignant Pleural Mesothelioma Enrollment increased: 9 → 10 participants
- Minor: Complement 3 Glomerulopathy (C3G) Patients Treated With Iptacopan Through an Early Access Program in Spain Trial sites expanded: 1 → 5 locations
- Minor: How Elinzanetant is Used and How Well it Works · Menopause Symptoms Trial sites expanded: 0 → 22 locations
- Minor: Fabry Disease Registry & Pregnancy Sub-registry Trial sites expanded: 284 → 289 locations
- Minor: MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study Trial sites expanded: 2393 → 2449 locations
- Minor: NeuroEndoscopic Surgery for Large IntraCerebral Hemorrhage Enrollment increased: 280 → 384 participants
- Minor: Molecular and Imaging Studies of Cardiovascular Health and Disease Enrollment increased: 5000 → 6000 participants
- Minor: Apalutamide (ARN-509) · Non-Metastatic Castration-Resistant Prostate Cancer Study completion pushed from Dec 31, 2027 to Dec 31, 2029
- Minor: Subcutaneous Nomlabofusp · Friedreich's Ataxia Start date changed from estimate of Oct 26, 2026 to Aug 5, 2026
- Minor: Tegacorat in Male Participants 4 to <7 Years of Age With Duchenne Muscular Dystrophy Start date pushed from Nov 9, 2026 to Nov 30, 2026
- Minor: Erdafitinib (JNJ-42756493) · Urothelial Cancer Study completion pushed from Mar 31, 2027 to Dec 31, 2027
- Minor: VG2025 Intravenous Injection · Advanced Solid Tumors Start date changed from estimate of Sep 4, 2026 to Nov 11, 2026
- Minor: ALKS 7290 as an Adjunctive Therapy to Antidepressants · Major Depressive Disorder Start date changed from estimate of Oct 2026 to Nov 9, 2026
- Minor: Partial Enteral Nutrition as Therapeutic Augmentation of Advanced Pharmacological Therapy · Active Crohn's Disease Trial sites expanded: 4 → 7 locations
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates